BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

BioMarin Pharmaceutical Inc.

Cantor Fitzgerald analyst Olivia Brayer reiterated a Buy rating on BioMarin Pharmaceutical yesterday and set a price target of $80.00. The company’...

Cantor Fitzgerald Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on BioMarin Pharmaceutical, with a price target of $66.00. The ...

BioMarin Pharmaceutical (BMRN) Gets a Hold from RBC Capital

Biomarin Pharmaceutical Inc. ( ($BMRN) ) has released its Q3 earnings. Here is a breakdown of the information Biomarin Pharmaceutical Inc. presente...

BioMarin Reports Strong Q3 2025 Revenue Growth

Biomarin Pharmaceutical Inc. (($BMRN)) announced an update on their ongoing clinical study. BioMarin Pharmaceutical Inc. is conducting a clinical s...

BioMarin’s Vosoritide Study: A Potential Game-Changer for Hypochondroplasia Treatment

Biomarin Pharmaceutical Inc. (($BMRN)) announced an update on their ongoing clinical study. BioMarin Pharmaceutical Inc. is conducting a Phase 3, o...

BioMarin’s Vosoritide Study: A Long-Term Hope for Hypochondroplasia

In a report released today, Gena Wang from Barclays maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $86.00. The company’...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMRN	$54.69	+4.21%	3.00M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMRN	$54.69	+4.2%	3.00M
3
4
5
6

BMRN

BMRN

Dividend Overview

Get BioMarin Pharmaceutical Inc. Data in Excel

Get BioMarin Pharmaceutical Inc. Data in Excel